Why DocuSign Shares Are Trading Higher Today

DocuSign Inc (NASDAQ: DOCU) is trading higher Friday after the company announced better-than-expected second quarter fiscal 2022 financial results and issued guidance above estimates. 

DocuSign Inc (NASDAQ:DOCU) is trading higher Friday after the company announced better-than-expected second quarter fiscal 2022 financial results and issued guidance above estimates. 

DocuSign reported quarterly earnings of 47 cents per share, which beat the estimate of 40 cents per share. The company reported quarterly revenue of $511.8 million, which beat the estimate of $487.5 million. 

DocuSign expects third-quarter fiscal 2022 revenue to be in a range of $526 million to $532 million versus the estimate of $520.62 million.

The company expects full-year fiscal 2022 revenue to be in a range of $2.078 billion to $2.088 billion versus the estimate of $2.05 billion.

“Organizations of all types and sizes are leveraging the power of the Agreement Cloud to digitize the most foundational process of doing business—the agreement process—starting with eSignature,” said Dan Springer, CEO of DocuSign.

Analyst Assessment: Multiple analyst firms raised price targets on the stock following the report:

  • Needham analyst Scott Berg maintained DocuSign with a Buy rating and raised the price target from $275 to $340.
  • Oppenheimer analyst Brian Schwartz maintained DocuSign with an Outperform rating and raised the price target from $260 to $310.
  • UBS analyst Karl Keirstead maintained DocuSign with a Buy rating and raised the price target from $340 to $350.
  • JMP Securities analyst Patrick Walravens maintained DocuSign with a Market Outperform rating and raised the price target from $310 to $320.
  • RBC Capital analyst Rishi Jaluria maintained DocuSign with an Outperform rating and raised the price target from $280 to $345.
  • Morgan Stanley analyst Stan Zlotsky maintained DocuSign with an Overweight rating and raised the price target from $295 to $350.

DOCU Price Action: has traded as high as $314.76 and as low as $179.49 over a 52-week period.

The stock was up 6.64% at $314.12 at time of publication.

Photo: courtesy of DocuSign.

Total
0
Shares
Related Posts
Read More

Cogent Biosciences Announced Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosisl; Announced 89% ORR in TKI-therapy Naïve Patients; 73% ORR in All Evaluable Patients with 27-wee…

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic m

COGT